Biotinylated Human Siglec-3 / CD33 Protein, Avitag™,His Tag
Proteins and Peptides
- 貨號 Cat. No.
- CD3-H82E7
- 規格 Size
- 200ug
- 品牌 Brand
- ACROBiosystems
- Species
- Human
- Conjugate
- Precision Avi
- Expression System
- HEK293
- Tag
- Avi Tag 、 His Tag
Description
Source :
Biotinylated Human Siglec-3, Avitag,His Tag (CD3-H82E7) is expressed from human 293 cells (HEK293). It contains AA Asp 18 - His 259 (Accession # AAH28152.1).
Molecule : Siglec-3
Synonyms : CD33,SIGLEC3,gp67
Format : Powder
Category : MABSol® Biotin Labeled Proteins
Accession : AAH28152.1
Storage : -20℃
Shipping condition : Powder,RT
Molecular Weight : 29.4 kDa
Characteristics :
This protein carries an Avi tag (Avitag™) at the C-terminus, followed by a polyhistidine tag. The protein has a calculated MW of 29.4 kDa. The protein migrates as 45-55 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
Endotoxin Level : Less than 1.0 EU per μg by the LAL method.
Buffer : PBS, pH7.4
Description :
Myeloid cell surface antigen CD33 is also known as SIGLEC3, Siglecs (sialic acid binding Iglike lectins) and GP67, is a single-pass type I membrane protein which belongs to the immunoglobulin superfamily and SIGLEC (sialic acid binding Ig-like lectin) family. Human CD33 / Siglec-3 cDNA encodes a 364 amino acid (aa) polypeptide with a hydrophobic signal peptide, an N-terminal Ig-like V-type domain, one Ig-like C2-type domains, a transmembrane region and a cytoplasmic tail. CD33 / Siglec-3 usually considered myeloid-specific, but it can also be found on some lymphoid cells. In the immune response, CD33 / Siglec-3 may act as an inhibitory receptor upon ligand induced tyrosine phosphorylation by recruiting cytoplasmic phosphatase(s) via their SH2 domain(s) that block signal transduction through dephosphorylation of signaling molecules. CD33 / Siglec-3 induces apoptosis in acute myeloid leukemia.
References :
(1) Garnache-Ottou F., et al., 2005, Blood 105 (3): 1256–64.
(2) Hernández-Caselles T, et al., 2006, J. Leukoc. Biol. 79 (1): 46–58.
(3) Walter RB, et al., 2007, Blood 109 (10): 4168–70.
(4) Ulyanova, T. et al., 1999, Eur. J. Immunol. 29:3440.
(5) Crocker, P.R. and A. Varki, 2001, Immunology 103:137.

